Huaier Granule in Combination With Nilaparil in Therapy Patients With Stage III/IV BRCA Wild-type Ovarian Cancer

Ovarian Cancer Clinical Trial

Official title:

Efficacy and Safety of Huaier Granule in Combination With Nilaparil in First-line Maintenance Therapy in Postoperative Patients With Stage III/IV BRCA Wild-type Ovarian Cancer: a Single-center Prospective, Single-arm Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05749211
• Other study ID #: 2023(02)
• Status: Not yet recruiting
• Phase: N/A
• Start date: May 2023
• Est. completion date: December 2025

Study information

• Verified date: January 2023
• Source: Ruijin Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single-center, prospective, single-arm clinical trial to evaluate the efficacy and safety of Huaier granules in combination with immunotargeted agents in postoperative patients with ovarian cancer.

Description:

Primary objective :

1) To evaluate the efficacy of Huaier granule combined with immunotargeted drugs in the treatment of postoperative ovarian cancer patients

Secondary objectives:

1)To analyze the safety of Huaier granule in the treatment of postoperative ovarian cancer patients; 2)2) To analyze the influence of Huaier granule on postoperative quality of life of patients with ovarian cancer.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 59
• Est. completion date: December 2025
• Est. primary completion date: December 2023
• Accepts healthy volunteers: No
• Gender: Female
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• According to FIGO criteria, participants must have a histological diagnosis of high-grade serous or endometrioid carcinoma, or high-grade serous or endometrioid predominantly ovarian, fallopian tube cancer, or stage III or IV primary peritoneal carcinoma

• Inoperable stage III and IV patients; All stage III and IV patients who can accept initial or intermittent tumor reduction surgery, regardless of the residual lesion status after surgery

• Patients who had undergone abdominal chemotherapy; All participants must undergo 6 and 9 cycles of platinum-based therapy; Participants were required to receive 2 cycles of postoperative platinum therapy following interphase tumor reduction surgery; Participants had to be assessed by a physician for complete response (CR) or partial response (PR) after 3 cycles of treatment; Participants had to have cancer antigen 125 (CA-125) within the normal range or ca-125 decreased by more than 90%(%) to be stable during their first-line therapy

• All participants must agree to be tested for central tumor BRCA

• Fertile participants must have a negative serum or urine pregnancy test (human chorionic gonadotropin [hCG]) within 7 days of receiving the first dose of study treatment.

Exclusion Criteria:

• Participants had epithelial ovarian carcinosarcoma or mucinous or clear cell subtypes of undifferentiated ovarian cancer

• The participants had already undergone more than two tumor-reduction surgeries for the study disease

• Participants became pregnant or lactated or expected to become pregnant during study treatment and 180 days after the last dose of study treatment

• Participants were known to be allergic to the ingredients or excipients of the study drug

• Participants had previously been treated with a known PARP inhibitor or had participated in any treatment group that included the use of a known PARP inhibitor

• Participants received bevacizumab maintenance therapy

• Subjects received investigational therapy within 4 weeks or at intervals not exceeding 5 investigational drug half-lives, whichever is longer, prior to the study's first scheduled dosing date

• Participants had known grade 3 anemia, neutropenia or thrombocytopenia that persisted due to prior chemotherapy. 4 weeks;

• Throughout the study treatment period, participants were treated with conditions (such as transfusion-dependent anemia or thrombocytopenia) or laboratory abnormalities that could confound study results or interfere with their participation, including:

• Participants received blood transfusions (platelets or red blood cells) within 2 weeks of the first dose of study treatment

• Participants received colony stimulating factor (e.g., granulocyte-colony-stimulating factor [G-CSF] or recombinant erythropoietin) within 2 weeks prior to the first dose of study treatment;

• Participants had been diagnosed and/or treated for invasive cancer less than 5 years prior to enrollment

Related Conditions & MeSH terms

• Carcinoma, Ovarian Epithelial
• Ovarian Cancer
• Ovarian Neoplasms

Intervention

Drug:
• Huaier granule
Oral administration, 20 g once, 3 times a day, continued until progression or intolerance of toxicity

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Ruijin Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression Free survival (PFS)	PFS according to the RECIST 1.1 criteria, based on the investigator's assessment.	up to 2 years from start of treatment
Secondary	Median Progression Free survival	mPFS is defined as the median time from study entry to date of first documented objective tumor recurrence according to RECIST 1.1	Every 3 month until 2 years from start of treatment
Secondary	1-year progression-free survival rate	The time from study entry to the time of disease progression as determined by the investigator (by clinical, radiological or pathological means) or death from any cause	up to 1 years
Secondary	Median overall survival	Median observed length of life from entry into the study to death; or for living patients, the date of last contact regardless of whether or not this contact is on a subsequent protocol	Every 3 month until 2 years from start of treatment
Secondary	1 year overall survival rate	Observed length of life from entry into the study to death; or for living patients, the date of last contact regardless of whether or not this contact is on a subsequent protocol.	1 year
Secondary	overall survival	OS is defined as the time from start of treatment to date of death due to any cause, or last patient contact	From study entry to death or last contact, up to 2 years of follow-up
Secondary	Quality of life score( EQ-5D)	questionnaires to be completed by patients and collected frequently during the trial	Every 3 month until 2 years from start of treatment
Secondary	Quality of life score(EORTC-QLQ-OV28)	Assessment of quality of life according to the QLQ-OV28/EORTC scales	Every 3 month until 2 years from start of treatment
Secondary	Quality of life score(EORTC-QLQ-C30)	Assessment of quality of life according to the QLQ-C30/EORTC scales	Every 3 month until 2 years from start of treatment
Secondary	Quality of life score(FACT-O)	The FACT-O questionnaire consists of a Physical Well-Being Section, Social/Family Well-Being Section, Emotional Well-Being Section, Functional Well-Being Section, and Additional Concerns Section	Every 3 month until 2 years from start of treatment
Secondary	the rates of AEs and SAEs	frequency of adverse events according to MedDRA terms	up to 2 years